SAN DIEGO, April 29, 2019 /PRNewswire/ -- Immunic, Inc.
(Nasdaq: IMUX), a clinical-stage biopharmaceutical
company focused on developing best-in-class, oral therapies
for the treatment of chronic inflammatory and autoimmune diseases,
today announced the appointment of Tamara
A. Seymour, MBA, as its Interim Chief Financial Officer,
effective April 26, 2019. Ms. Seymour
is a corporate finance veteran with three decades of experience in
the biotech and life sciences industries.
"Ms. Seymour has a proven track record of guiding public and
privately-held life sciences companies through their corporate life
cycles, including capital raising, negotiating complex strategic
transactions, setting and maintaining internal fiscal policy and
driving revenue growth," stated Daniel
Vitt, Ph.D., Chief Executive Officer and President of
Immunic. "Her range of expertise and relevant leadership skills
will serve us well as we drive the development of our lead
compound, IMU-838, now in phase 2 clinical trials for ulcerative
colitis and relapsing-remitting multiple sclerosis, as well as our
other pipeline assets."
Since 2018, Ms. Seymour has served as a financial advisor,
assisting life sciences companies with merger and acquisition
activities and other finance-related needs. From 2014 to 2017, she
served as Chief Financial Officer of Signal Genetics Inc. (now
miRagen Therapeutics, Inc.), a publicly traded commercial-stage,
molecular genetic diagnostics company focused on multiple myeloma.
From 2010 to 2014, Ms. Seymour served as Chief Financial Officer of
Hemaquest Pharmaceuticals, Inc., a venture-backed clinical
development stage biotechnology company developing proprietary
small molecules for the treatment of life-threatening hematologic
disorders. From 2001 to 2009, Ms. Seymour served as Chief Financial
Officer of Favrille, Inc. (now MMR Global, Inc.), a publicly traded
clinical development stage biopharmaceutical company developing
therapeutic vaccines for non-Hodgkin's lymphoma. While at Favrille,
she was instrumental in raising more than USD 200 million in multiple private and public
equity and debt financings, including the company's IPO. Earlier in
her career, Ms. Seymour consulted as Chief Financial Officer for a
number of biotechnology companies and served for more than eight
years in various positions, including audit manager, with Deloitte
LLP and PricewaterhouseCoopers LLP. She is currently a member of
the board of directors and audit committee chair of Beacon
Discovery, Inc., a privately-held company working to identify and
advance molecules targeting G protein-coupled receptors.
Ms. Seymour is a certified public accountant (inactive). She
received an MBA, with an emphasis in finance, from Georgia State University and earned her BBA, with
an emphasis in accounting, from Valdosta State
University.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX)
is a clinical-stage biopharmaceutical company developing a
pipeline of selective oral immunology therapies aimed at treating
chronic inflammatory and autoimmune diseases, including ulcerative
colitis, Crohn's disease, relapsing-remitting multiple sclerosis,
and psoriasis. The company is developing three small molecule
products: IMU-838 is a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856
targets the restoration of the intestinal barrier function.
Immunic's lead development program, IMU-838, is in phase 2 clinical
development for ulcerative colitis and relapsing-remitting multiple
sclerosis, with an additional phase 2 trial in Crohn's disease
planned for 2019. An investigator-sponsored proof-of-concept
clinical trial for IMU-838 in primary sclerosing cholangitis is
planned to start at the Mayo Clinic. For further information,
please visit: www.immunic-therapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
Immunic's listing on The Nasdaq Capital Market; expectations
regarding the capitalization, resources and ownership structure of
the company; the potential for IMU-838, IMU-935 and IMU-856 to
safely and effectively target diseases; the adequacy of the
company's capital to support its future operations and its ability
to successfully initiate and complete clinical trials; the nature,
strategy and focus of the company; the development and commercial
potential of any product candidates of the company; and the
executive and board structure of the company. Immunic may not
actually achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, risks
and uncertainties associated with the ability to project future
cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient
resources to meet business objectives and operational requirements,
the fact that the results of earlier studies and trials may not be
predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made.
Contact Information
Immunic, Inc.
Jessica
Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de
Or
Rx Communications Group
Melody Carey
+1-917-322-2571
immunic@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-appoints-industry-veteran-tamara-a-seymour-as-interim-chief-financial-officer-300839639.html
SOURCE Immunic, Inc.